

**Gedeon Richter**

**Report to the Budapest Stock Exchange  
9 months to September 2022**

## Contents

Contents.....	2
Executive Summary .....	4
Extraordinary events impacting the reporting period.....	5
Notes to Specialty Sales.....	6
Notes to Pharmaceutical Sales.....	12
Background Information on Pharmaceutical Sales .....	15
Background Information on Wholesale and Retail Sales .....	16
Information on Business Segments .....	17
Consolidated Financial Statements .....	18
Consolidated Balance Sheet – Assets .....	18
Consolidated Balance Sheet – Equity and Liabilities .....	19
Consolidated Statement of Changes in Equity .....	20
Consolidated Income Statement – HUF .....	22
Consolidated Income Statement – EUR.....	23
Consolidated Income Statement – 3 months to September HUF, EUR .....	24
Consolidated Cash-flow Statement.....	25
Notes to Consolidated Financial Statements .....	26
Corporate matters .....	31
Risk management .....	33
Disclosures.....	34

Consolidated figures are prepared in accordance with relevant IFRS regulations and presented in million Hungarian Forint (HUFm). The Report may also contain figures in other currencies but only for indicative purposes.


Detailed explanations to selected items presented in the tables are offered in the two ‘Notes’ sections as numbered in the respective tables.

“Our growth performance remained broad based in both geographic terms and across product segments. The rare combination of simultaneous USD and RUB strength gave a massive uplift to the already robust underlying trend in both sales revenues and overall profitability. Financial income was also given an extra boost as both USDHUF and RUBHUF peaked near the end of the reporting period.

Motivated by our mission to bring innovation to the women’s health space, we recently submitted a request for Ryeqo® to be authorised in the endometriosis indication in the EU. Our global WHC franchise was further reinforced by several new marketing authorisations that we obtained in the third quarter 2022 for flagship products in China, Brazil, and Australia.

We successfully negotiated and in October we signed the divestment of our wholesale and retail business in Romania. This follows a similar deal in Moldova last year as we continue streamlining and refocusing our operations.”

Gábor Orbán



## Executive Summary

Consolidated sales	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Total	578,787	454,321	124,466	27.4	1,494.1	1,275.3

Pharma sales	HUFm				Notes	EURm	
	2022	2021	Change			2022	2021
	9 months to September					9 months to September	
				%			
Hungary	33,538	31,451	2,087	6.6	6)	86.6	88.3
Europe*	143,371	113,181	30,190	26.7	7)	370.1	317.7
CEE	64,296	53,079	11,217	21.1		166.0	149.0
WEU	79,075	60,102	18,973	31.6		204.1	168.7
CIS	122,714	90,235	32,479	36.0	8)	316.8	253.3
Russia	89,980	61,174	28,806	47.1		232.3	171.7
Ukraine	7,797	9,883	-2,086	-21.1		20.1	27.8
Other CIS	24,937	19,178	5,759	30.0		64.4	53.8
USA	117,543	86,194	31,349	36.4	9)	303.4	241.9
China	15,746	10,300	5,446	52.9	10)	40.6	28.9
Latin America	14,452	9,889	4,563	46.1	11)	37.3	27.7
RoW	25,749	22,465	3,284	14.6	12)	66.5	63.1
Total	473,113	363,715	109,398	30.1		1,221.3	1,020.9

\* excluding Hungary

Specialty sales	HUFm				Notes	EURm	
	2022	2021	Change			2022	2021
	9 months to September					9 months to September	
				%			
cariprazine	103,758	74,329	29,429	39.6	1)	267.8	208.6
Vraylar® royalty (USA)	98,518	71,252	27,266	38.3		254.3	200.0
Vraylar® royalty (CA)	16	0	16	n.a.		0.0	0.0
Reagila®	5,224	3,077	2,147	69.8		13.5	8.6
WHC	171,157	124,594	46,563	37.4	2)	441.8	349.7
Bemfola®	15,649	14,983	666	4.4	3)	40.4	42.1
Evra®	19,717	9,704	10,013	103.2	4)	50.9	27.2
OCs	98,713	76,141	22,572	29.6		254.8	213.7
teriparatide	14,901	9,273	5,628	60.7	5)	38.5	26.1
Total	289,816	208,196	81,620	39.2		748.1	584.4
Proportion to Pharma sales (%)	61.3	57.2					

Wholesale and retail sales	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Total	112,045	97,179	14,866	15.3	289.2	272.8

Approximate exchange rate gain at consolidated sales level: HUF +72.0bn

**Selected exchange rates – period averages**

	2022 M9	2021 M9
EURHUF	387.39	356.25
USDHUF	365.83	298.08
RUBHUF	5.46	4.02
CNYHUF	54.60	46.11

**Exchange rate impact on main consolidated P&L items**

As a result of an extraordinary FX environment which prevailed during most of the reported period our business has been significantly impacted by exchange rate gains. We have, consequently decided to highlight the level of such FX related gains at individual P&L items. As the basis for the calculations is that which is used in our internal management accounting, the below figures should be perceived as approximate amounts.

HUFbn	2022 M9
Sales	72.0
Gross profit	54.6
Operating profit	38.5

**Selected consolidated business metrics**

	HUFm	
	2022	2021
	9 months to September	
Gross margin %	58.2	55.5
Operating margin %	26.7	20.7
Profit margin attributable to owners of the parent %	33.9	20.5

**Extraordinary events impacting the reporting period****Russian – Ukrainian conflict**

Russia initiated military action in Ukraine in late February, following Moscow's recognition of the Donbass republics of Donetsk and Lugansk.

Providing a safe and sustainable supply of medicines to both patients and healthcare professionals is the utmost responsibility of any pharmaceutical company. In that spirit, similarly to all multinational pharmaceutical companies, we continued to supply Russian patients with our products.

Business in Russia suffered slight temporary delays in the early days of the conflict, but shipments have since then broadly returned to their pre-war routine. Shipments are made via road freight transport mainly through Belarus. Market intelligence data suggest that in the first

eight months retail pharmaceutical sales in Russia increased by 23% in RUB terms primarily due to price increases.

A stockpiling impacted sales at the final consumer level in the first quarter. Wholesaler stocks, however, declined to significantly lower levels by the end of the first nine months 2022 when compared to their January position. Payments have been received in due order during the entire reported period.

Commercial operations which were disrupted in Ukraine in late February only resumed in mid April at significantly lower levels compared to previous sales volumes. Due to a recent change in Ukrainian legislation, marketing authorizations issued for products having sufficient competitors on the market may be revoked if their manufacturer operates manufacturing units and pays taxes in Russia. A procedure implementing the suspension of 35 of our products was initiated in early October on this legal basis. Richter plans to appeal against the decision.

Richter offered humanitarian relief to the local population at large and assisted its employees who had left the country providing them and their families with housing and employment in Hungary. Sales realised to Ukraine during the first nine months were paid in full by our partners.

As of March 2022 we have served Russian wholesalers exclusively from the Gedeon Richter RUS warehouse. Invoices are issued in RUB as previously. Approximately half of our local turnover is naturally hedged, covering the RUB incurred costs of local manufacturing and marketing activities. The remainder is hedged in HUF using forward contracts with well established banks with subsidiaries both in Russia and in the EU.

Hungarian Export Credit Insurer (MEHIB) suspended new contracting for Russian, Belorussian and Ukrainian buyers' credit in late February/early March 2022. Risks related to buyers' credit were therefore mitigated via credit insurances preceding that date and alternative methods (e.g. advance payments, financial guarantees) have been implemented since then. Russian subsidiaries of the Group have at their disposal significant reserves; nevertheless, risks around logistics and supply chains continue to be closely monitored.

## Notes to Specialty Sales

### 1) Cariprazine – Central Nervous System

**Vraylar® royalty income** due to Richter in the nine months to September 2022 amounted to HUF 98,534m (USD 269.3m). This amount contributed materially to the sales levels achieved during the reported period. As Richter maintains its accounts in HUF the above royalty income was accounted for at its corresponding HUF value and the latter amount was reconverted into USD for presentation purposes only using the current period's average exchange rate. The figures above also include royalty income paid in respect of AbbVie sales recorded in Canada during the third quarter 2022.

**Proceeds from Reagila®** amounted to HUF 5,224m (EUR 13.5m) during the reported period.

Figures shown in the following table are actual figures except for royalty income recorded in the third quarter 2022 in respect of **Vraylar®** and **Reagila®**.

	Turnover (Royalties included)				
	2022 Q3	2022 Q2	2022 Q1	2021 Q4	2021 Q3
USDm / <b>Vraylar®</b> (royalty (USA+CA)+API)	103.0	85.5	82.3	97.7	91.6
EURm / <b>Reagila®</b> (royalty+product sales)	4.3	4.9	4.3	4.2	3.3

## Recent developments

### USA

In late October 2021 Richter's partner, AbbVie announced that both phase III clinical trials which were ongoing in the USA to determine efficacy, safety, and tolerability of cariprazine as an adjunctive treatment of Major Depressive Disorder (aMDD) had been completed. In one of the studies cariprazine showed a statistically significant change to week six in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score compared with placebo while in the other in spite of showing positive results it did not reach statistical significance at its primary endpoints.

Based on the positive results of the clinical studies and all the necessary data reported, AbbVie submitted during the first quarter 2022 a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration for the expanded use of cariprazine for the adjunctive treatment of aMDD, which was accepted for review in late April.

### Canada

On 27 April 2022 Richter's partner, AbbVie announced that Health Canada has approved **Vraylar®** (cariprazine) as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar I disorder in adults, as well as the treatment of schizophrenia in adults. First royalty proceeds were accounted for in respect of Canadian sales realised during the third quarter 2022.

## Cariprazine market situation

### WEU

Country	Launch	Reimbursed launch
Germany	Q2 2018	yes
UK	Q3 2018	yes
Finland	Q4 2018	yes
Sweden	Q4 2018	yes
Denmark	Q4 2018	yes
Netherlands	Q4 2018	yes
Italy	Q1 2019	yes
Ireland	Q3 2019	yes
Spain	Q3 2019	yes
Portugal	Q3 2019	yes
Belgium	Q1 2020	no*
Luxembourg	Q3 2020	yes
Austria	Q1 2021	no
Greece	Q3 2021	yes

### CEE

Country	Launch	Reimbursed launch
Poland	Q1 2018	no*
Estonia	Q1 2018	no*
Slovenia	Q3 2018	yes
Hungary	Q4 2018	yes
Romania	Q4 2018	no
Bulgaria	Q1 2019	yes
Slovakia	Q1 2019	yes
Czech Republic	Q1 2019	yes
Latvia	Q2 2019	no*
Lithuania	Q1 2020	no
Croatia	Q4 2021	no

### Europe – Countries outside the European region

Country	Launch	Reimbursed launch
Switzerland	Q4 2018	yes
Norway	Q2 2019	yes
Montenegro	Q1 2020	yes
Serbia	Q1 2020	no*

### CIS

Country	Launch	Reimbursed launch
Russia	Q4 2019	yes
Moldavia	Q4 2019	no
Ukraine	Q1 2020	no
Belarus	Q1 2020	no
Georgia	Q1 2020	no
Kazakhstan	Q1 2020	no
Uzbekistan	Q1 2020	no
Azerbaijan	Q3 2020	no

### Other markets

Country	Launch	Reimbursed launch
Singapore	Q2 2020	no
Thailand	Q2 2020	no
Jordan	Q3 2020	no
Israel	Q4 2020	no**
Saudi Arabia	Q1 2021	no
Egypt	Q2 2021	no
Australia	Q3 2021	yes
United Arab Emirates	Q4 2021	no
Qatar	Q4 2021	no
Indonesia	Q2 2022	no
Canada	Q3 2022	no

\* Received reimbursement following the launch.

\*\* Reimbursed in schizophrenia indication, reimbursement for bipolar mania and depression is in progress.

Altogether by the end of first three quarters 2022 cariprazine was available in 49 countries globally including the USA and Hungary, with reimbursement in most countries where a reimbursement system is in place.

## 2) Women's Healthcare – Core Business

### WHC sales by region

	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Hungary	3,844	3,456	388	11.2	9.9	9.7
Europe*	77,226	60,239	16,987	28.2	199.4	169.1
CEE	19,667	15,061	4,606	30.6	50.8	42.3
WEU	57,559	45,178	12,381	27.4	148.6	126.8
CIS	41,613	26,360	15,253	57.9	107.4	74.0
Russia	35,167	20,594	14,573	70.8	90.8	57.8
Ukraine	1,799	2,430	-631	-26.0	4.6	6.8
Other CIS	4,647	3,336	1,311	39.3	12.0	9.4
USA	12,487	8,429	4,058	48.1	32.2	23.6
China	11,578	7,945	3,633	45.7	29.9	22.3
Latin America	12,644	8,093	4,551	56.2	32.6	22.7
RoW	11,765	10,072	1,693	16.8	30.4	28.3
Total	171,157	124,594	46,563	37.4	441.8	349.7

\* excluding Hungary

WHC sales in the first three quarters 2022 exceeded levels recorded in the same period of the previous year by HUF 46,563m or 37.4%. Higher sales levels were recorded in all of our regions except for Ukraine.

Sales of the WHC product group increased due to turnover of oral contraceptives and the royalty and direct sales income received from [Evra](#)<sup>®</sup>. [Drovelis](#)<sup>®</sup> launched in the second quarter 2021 also contributed materially to sales levels achieved during the reported period. In addition to the above, turnover of emergency contraceptive [Plan B](#) and certain steroid APIs further lifted US sales.

In line with our endeavour to bring innovative products to our Women's Health franchise marketing approvals were granted in the third quarter 2022 for our drospirenone containing, fourth generation OC in China and for [Ryeqo](#)<sup>®</sup> in uterine fibroid indication in Australia.

## WHC sales by product groups

	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September		%		9 months to September	
Oral contraceptives	98,713	76,141	22,572	29.6	254.8	213.7
Drovelis®	3,844	238	3,606	1,515.1	9.9	0.7
Non-oral contraceptives	22,875	11,531	11,344	98.4	59.1	32.4
Evra®	19,717	9,704	10,013	103.2	50.9	27.2
Infertility	18,855	17,226	1,629	9.5	48.7	48.4
Bemfola®	15,649	14,983	666	4.4	40.4	42.1
Cyclogest®	2,966	2,013	953	47.3	7.7	5.7
Other WHC therapies	30,714	19,696	11,018	55.9	79.2	55.2
Ryeqo®	1,246	62	1,184	1,909.7	3.2	0.2
Lenzetto®	4,131	2,596	1,535	59.1	10.7	7.3
<b>Total</b>	<b>171,157</b>	<b>124,594</b>	<b>46,563</b>	<b>37.4</b>	<b>441.8</b>	<b>349.7</b>

## Proportion of WHC sales to total pharmaceutical turnover – by region

	%	
	2022	2021
	9 months to September	
Hungary	11.4	11.0
Europe*	53.9	53.2
CEE	30.6	28.4
WEU	72.8	75.2
CIS	33.9	29.2
USA	10.6	9.8
China	73.6	77.2
Latin America	87.4	81.9
RoW	45.7	44.8
<b>Total</b>	<b>36.2</b>	<b>34.3</b>

\* excluding Hungary

## Western Europe Top 5 markets

	MEUR	
	2022	2021
	9 months to September	
Germany	28.7	27.4
Spain	26.6	24.8
Italy	22.6	17.2
France	19.1	15.3
UK	17.3	13.5
<b>Total Top 5 Sales</b>	<b>114.3</b>	<b>98.2</b>
<b>Total WEU Sales</b>	<b>148.6</b>	<b>126.8</b>
<b>Total Top 5 Sales %</b>	<b>76.9</b>	<b>77.4</b>

## 3) Bemfola® – Women’s Healthcare

	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Hungary	587	557	30	5.4	1.5	1.6
Europe*	13,242	11,806	1,436	12.2	34.2	33.2
CEE	1,652	1,410	242	17.2	4.3	4.0
WEU	11,590	10,396	1,194	11.5	29.9	29.2
CIS	-2	122	-124	-101.6	0.0	0.3
Latin America	188	3	185	6,166.7	0.5	0.0
RoW	1,634	2,495	-861	-34.5	4.2	7.0
Total	15,649	14,983	666	4.4	40.4	42.1

\* excluding Hungary

The positive impact of the removal of previous restrictions related to the COVID-19 pandemic led to rebounding sales of Bemfola® on most markets partly offset by declining sales recorded in Australia. Turnover achieved by the product in the nine months to September 2022 amounted to HUF 15,649m, exceeding base figures by HUF 666m or 4.4% primarily due to proceeds from WEU region. Sales proceeds from South Korea also contributed to the higher turnover reported. Negative sales recorded in Ukraine were due to credit notes issued to wholesalers in respect of sales realised in the last quarter 2021. In EUR terms sales performance of this product reported for the first three quarters 2022 declined by EUR 1.7m when compared to the performance of the same period in 2021.

## 4) Evra® – Women’s Healthcare

	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Hungary	14	-	14	n.a.	0.0	-
Europe*	8,485	3,918	4,567	116.6	21.9	11.0
CEE	1,987	783	1,204	153.8	5.1	2.2
WEU	6,498	3,135	3,363	107.3	16.8	8.8
CIS	435	197	238	120.8	1.1	0.6
Latin America	6,309	3,008	3,301	109.7	16.3	8.4
RoW	4,474	2,581	1,893	73.3	11.6	7.2
Total	19,717	9,704	10,013	103.2	50.9	27.2

\* excluding Hungary

The asset purchase agreement concluded in January 2021 with Janssen Pharmaceutica NV and the complementary transitional business licence agreement provided for post-closing transitional support to facilitate the transfer of the Outside US marketing authorizations. Royalty type revenues linked to sales of Evra® and paid by Janssen during this transitional period are being reported as sales. In the reported period Evra® ranked 4<sup>th</sup> on our Top10 products list.

Direct sales of this product amounted to HUF 12,838m (EUR 33.1m) in the first three quarters 2022 while royalty income recorded by **Evra**<sup>®</sup> totalled HUF 6,813m (EUR 17.6m) during the same period.

#### 5) Teriparatide – biosimilar portfolio

Total sales proceeds from teriparatide amounted to HUF 14,901m (EUR 38.5m) in the nine months to September 2022 period. Richter launched its biosimilar, **Terrosa**<sup>®</sup> in the EU in August 2019 while its license partner, Mochida Pharmaceuticals introduced the product in Japan in late November of the same year. In addition to the above, the product was launched during 2020 by Daewon Pharmaceutical Co. Ltd. in South Korea and by Avir Pharma Inc. in Canada, while our Israeli partner, Dexcel Pharma received marketing authorization for the product in the same year. The product was launched in March 2021 on the Israeli market. Sales proceeds from Japan contributed HUF 2,881m representing 19% of total sales achieved by the product.

## Notes to Pharmaceutical Sales

#### 6) Hungary

The underlying market increased by 9.7% while retail sales of Richter products increased at a higher rate of 11.2% according to the latest available IQVIA (successor of IMS) data. The Company is now ranked fourth amongst players in the Hungarian pharmaceutical market with a market share of 4.5%. Taking into account the prescription drugs retail market alone, Richter qualifies for second place with a market share of 7.4%.

#### 7) Europe

The **Central and Eastern European** region sales represented 45% of total European sales of the Group's pharmaceutical segment.

Turnover recorded in **Poland** increased by HUF 4,478m (PLN 305.7m), or 21.7% (16.1%) in the first three quarters of 2022 and totalled HUF 25,119m. Higher sales of **Evra**<sup>®</sup>, which was launched directly by Richter in January 2022 together with turnover from **Drovelis**<sup>®</sup> have contributed the most to the turnover achieved. Following a drop in sales of **Groprinosin** in the second year of the pandemic, sales of this product gained momentum again in the reported period. As **Reagila**<sup>®</sup> received reimbursed status in the last quarter 2021 Richter intensified its promotional efforts and proceeds of this product also contributed positively to turnover recorded in this market.

In **Romania** total sales were HUF 11,612m (RON 149.0m) during the reported period. Sales growth of HUF 2,423m, 26.4% (RON 22.3m, 17.6%) resulted primarily from well-established branded generic products partly subsequent to a low base period performance. As a result of certain price modifications implemented at the beginning of March 2022 by the regulatory authority, substantial price increases could be recorded for some of our products.

Turnover in the **Western European** region increased substantially by HUF 18,973m or 31.6% (EUR 35.4m, 21.0%). Growth recorded in France, Italy, Spain and UK contributed the most to the sales level achieved during the reported period. As far as the product portfolio is concerned increasing proceeds from **Terrosa**<sup>®</sup> and **Evra**<sup>®</sup> were complemented by turnover of recently launched **Drovelis**<sup>®</sup>. In addition, proceeds from contract manufacturing activities at Richter-Helm Biologics also contributed to the substantial growth reported in this region. WEU sales represented 55% of total European pharmaceutical turnover.

## 8) CIS

Sales to **Russia** at HUF 89,980m (RUB 16,479.8m) increased by 47.1% in HUF terms (8.3% in RUB terms). The RUB appreciated against the HUF on an average by 35.8% compared to the first nine months 2021. Notwithstanding a volatile market environment presenting unforeseeable risks connected to the ongoing war and the subsequent sanctions imposed on Russia, business operations prevailed at levels experienced prior to the pandemic.

In the first quarter 2022 an overall 23% price increase was implemented to our portfolio of non-essential drugs. These price adjustments implemented at the end of the first quarter impacted turnover by 12.9% as far as the figures reported for the nine months to September 2022 period are concerned. The slight decrease in volumes delivered in both the second and the third quarter 2022 were more than offset at retail levels by lower stocks held by wholesalers.

In-market sales figures (IQVIA, data relative to the first eight months) suggest that sales recorded in RUB terms by Richter products at retail level increased by 23.3% broadly in line with overall market growth at 23.2% in RUB terms primarily related to price increases implemented by manufacturers and distributors during the first quarter 2022.

Sales of originator products together with performance of some local producers reported a significant increase during the reported period while most generic manufacturers recorded sales in line with Richter's performance when expressed in RUB terms.

Sales levels during the three quarters of 2022 at EUR 232.3m increased by EUR 60.6m when compared to the same period in 2021 as the growth achieved in EUR terms was further boosted by a stronger EURRUB average exchange rate experienced during the reported period.

As a result of the uncertain financial environment Richter has stopped direct sales to distributors from Hungary to Russia switching instead to sales via Gedeon Richter RUS, the Group's local manufacturing unit and warehouse. To date we have not experienced any financial disruption to the timely payment of outstanding invoices.

Sales reported in **Ukraine** in the first three quarters 2022, at EUR 20.1m declined by 27.7%. These figures include sales realised up to late February, together with turnover achieved since mid April. Due to a recent change in Ukrainian legislation, marketing authorizations issued for products having sufficient competitors on the market may be revoked if their manufacturer operates manufacturing units and pays taxes in Russia. A procedure implementing the suspension of 35 of our products was initiated in early October on this legal basis. Richter plans to appeal against the decision. Sales to **Other CIS** markets reported a turnover of HUF 24,937m, representing a HUF 5,759m increase when compared to the sales performance achieved in the first three quarters 2021.

Higher turnover was primarily recorded in Uzbekistan and Kazakhstan. Weakening of EUR against USD during the reported period impacted unfavourably EUR denominated sales proceeds in certain markets of the region partly offsetting the achieved overall good turnover reported in this group of countries.

**9) USA**

Sales to the **USA**, our leading market as far as revenue is concerned, increased by HUF 31,349m (36.4%) or USD 32.1m (11.1%). Royalty revenues linked to **Vraylar®** amounted to HUF 98,518m (USD 269.3m), a growth of 38.3% (12.7% in USD terms) when compared to first nine months to September 2021.

An increase in API sales also impacted positively our performance achieved.

**10) China**

Richter's Management considers this market to be of high importance and it focuses on the promotion of the current WHC portfolio while at the same time having a strategic objective to further enhance this product line. Sales growth of HUF 5,446m (52.9%) arose primarily from the higher sales of **Escapelle** and **Panangin** together with turnover from **Bromocriptin** resulting from the uneven timing of shipments. Marketing authorization was issued during the third quarter concerning one of our fourth generation OCs containing drospirenone.

**11) Latin America**

Higher turnover was recorded in most countries of this region, out of which the performance of Mexico contributed primarily to the higher sales levels. As for the product portfolio, royalty proceeds and direct sales of **Evra®** contributed the most to the turnover achieved.

**12) Rest of the World**

Higher sales levels of **Evra®** and teriparatide contributed primarily to the sales growth achieved during the reported period. Geographically, growth was driven by higher turnover recorded in Norway, Japan and Canada.

## Background Information on Pharmaceutical Sales

by region in currencies of invoicing

	Currency (million)	2022 9 months to September	2021 9 months to September	Change %
Hungary	HUF	33,538	31,451	6.6
Europe*	EUR	370.1	317.7	16.5
CEE	EUR	166.0	149.0	11.4
WEU	EUR	204.1	168.7	21.0
CIS	EUR	316.8	253.3	25.1
	USD	335.5	302.7	10.8
Russia	RUB	16,479.8	15,217.5	8.3
Ukraine	EUR	20.1	27.8	-27.7
Other CIS	EUR	64.4	53.8	19.7
	USD	68.2	64.3	6.1
USA	USD	321.3	289.2	11.1
China	CNY	288.4	223.4	29.1
Latin America	USD	39.5	33.2	19.0
RoW	EUR	66.5	63.1	5.4
	USD	70.4	75.3	-6.5

\* excluding Hungary

to Top 10 markets

	HUFm				EURm	
	2022 9 months to September	2021 9 months to September	Change %		2022 9 months to September	2021 9 months to September
USA	117,543	86,194	31,349	36.4	303.4	241.9
Russia	89,980	61,174	28,806	47.1	232.3	171.7
Hungary	33,538	31,451	2,087	6.6	86.6	88.3
Poland	25,119	20,641	4,478	21.7	64.8	57.9
Germany	17,787	17,413	374	2.1	45.9	48.9
China	15,746	10,300	5,446	52.9	40.6	28.9
Spain	14,865	11,595	3,270	28.2	38.4	32.5
Romania	11,612	9,189	2,423	26.4	30.0	25.8
France	11,360	6,413	4,947	77.1	29.3	18.1
Italy	10,330	6,823	3,507	51.4	26.7	19.2
Total Top 10	347,880	261,193	86,687	33.2	898.0	733.2
Total Sales	473,113	363,715	109,398	30.1	1,221.3	1,020.9
Total Top 10 / Total Sales %					73.5	71.8

## of Top 10 products

	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Vraylar® / Reagila® / cariprazine Oral	104,303	74,733	29,570	39.6	269.2	209.8
contraceptives	98,713	76,141	22,572	29.6	254.8	213.7
Mydeton / Mydocalm	20,053	12,908	7,145	55.4	51.8	36.2
Evra®	19,717	9,704	10,013	103.2	50.9	27.2
Bemfola®	15,649	14,983	666	4.4	40.4	42.1
Terrosa® / teriparatide	14,901	9,273	5,628	60.7	38.5	26.1
Cavinton	13,717	12,629	1,088	8.6	35.4	35.4
Verospiron	13,395	11,524	1,871	16.2	34.6	32.3
Panangin	13,154	10,824	2,330	21.5	34.0	30.4
Aflamin	10,632	8,641	1,991	23.0	27.4	24.3
<b>Total Top 10</b>	<b>324,234</b>	<b>241,360</b>	<b>82,874</b>	<b>34.3</b>	<b>837.0</b>	<b>677.5</b>
<b>Total Sales</b>	<b>473,113</b>	<b>363,715</b>	<b>109,398</b>	<b>30.1</b>	<b>1,221.3</b>	<b>1,020.9</b>
<b>Total Top 10 / Total Sales %</b>					<b>68.5</b>	<b>66.4</b>

## Background Information on Wholesale and Retail Sales

	HUFm				EURm	
	2022	2021	Change		2022	2021
	9 months to September				9 months to September	
				%		
Hungary	0	2	-2	-100.0	0.0	0.0
Europe*	102,471	83,870	18,601	22.2	264.5	235.4
CEE	102,471	83,870	18,601	22.2	264.5	235.4
CIS	4,581	9,818	-5,237	-53.3	11.8	27.6
Other CIS	4,581	9,818	-5,237	-53.3	11.8	27.6
Latin America	4,993	3,489	1,504	43.1	12.9	9.8
<b>Total</b>	<b>112,045</b>	<b>97,179</b>	<b>14,866</b>	<b>15.3</b>	<b>289.2</b>	<b>272.8</b>

\* excluding Hungary

## Information on Business Segments

	Pharmaceuticals		Wholesale and retail		Other		Eliminations		Group total	
	9 months to September 2022	2021	9 months to September 2022	2021	9 months to September 2022	2021	9 months to September 2022	2021	9 months to September 2022	2021
	Not audited	Not audited	Not audited	Not audited	Not audited	Not audited	Not audited	Not audited	Not audited	Not audited
<b>P&amp;L items HUFm</b>										
<b>Revenues</b>	<b>473,113</b>	<b>363,715</b>	<b>112,045</b>	<b>97,179</b>	<b>6,599</b>	<b>5,098</b>	<b>(12,970)</b>	<b>(11,671)</b>	<b>578,787</b>	<b>454,321</b>
Cost of sales	(145,881)	(119,645)	(102,904)	(89,643)	(6,139)	(4,556)	12,841	11,682	(242,083)	(202,162)
Gross profit	327,232	244,070	9,141	7,536	460	542	(129)	11	336,704	252,159
<b>Profit from operations</b>	<b>152,696</b>	<b>93,309</b>	<b>172</b>	<b>336</b>	<b>206</b>	<b>289</b>	<b>1,221</b>	<b>-</b>	<b>154,295</b>	<b>93,934</b>
Net financial income	54,270	6,253	5	(250)	29	6	(2,994)	(4,203)	51,310	1,806
<b>Miscellaneous items</b>										
Capital expenditure HUFm	43,324	119,882	70	468	202	151	-	(16)	43,596	120,485
Number of employees at the end of the period	10,703	10,801	1,096	1,125	381	402	-	-	12,180	12,328
<b>Business metrics %</b>										
Gross margin	69.2	67.1	8.2	7.8	7.0	10.6	-	-	58.2	55.5
Operating margin	32.3	25.7	0.2	0.3	3.1	5.7	-	-	26.7	20.7

## Consolidated Financial Statements

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

### Consolidated Balance Sheet – Assets

	<b>30 September 2022</b>		<b>31 December 2021</b>	<b>Change</b>
	<b>Not audited HUFm</b>	<b>Notes</b>	<b>Audited HUFm</b>	<b>%</b>
<b>ASSETS</b>	<b>1,385,033</b>		<b>1,145,282</b>	<b>20.9</b>
<b>Non-current assets</b>	<b>782,883</b>	<b>13)</b>	<b>732,660</b>	<b>6.9</b>
Property, plant and equipment	314,552		278,394	13.0
Investment property	125		110	13.6
Goodwill	40,174		35,005	14.8
Other intangible assets	214,296		220,915	-3.0
Investments in associates and joint ventures	8,934		10,800	-17.3
Non-current financial assets at amortised cost	7,816		5,335	46.5
Non-current financial assets at FVTPL	99,562		93,758	6.2
Non-current financial assets at FVOCI	80,486		73,274	9.8
Deferred tax assets	13,077		12,285	6.4
Long term receivables	3,861		2,784	38.7
<b>Current assets</b>	<b>602,150</b>	<b>14)</b>	<b>412,622</b>	<b>45.9</b>
Inventories	170,215		131,349	29.6
Contract assets	6,605		3,865	70.9
Trade receivables	207,486		184,760	12.3
Other current assets	51,124		30,474	67.8
Current financial assets at amortised cost	21,948		912	n.a.
Current financial assets at fair value	4,125		296	n.a.
Current tax asset	(672)		1,110	n.a.
Cash and cash equivalents	71,788		59,856	19.9
Assets classified as held for sale	69,531		-	n.a.

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

## Consolidated Balance Sheet – Equity and Liabilities

	30 September 2022 Not audited HUFm	Notes	31 December 2021 Audited HUFm	Change %
<b>EQUITY AND LIABILITIES</b>	<b>1,385,033</b>		<b>1,145,282</b>	<b>20.9</b>
Capital and reserves	1,106,697	15)	923,022	19.9
Share capital	18,638		18,638	0.0
Treasury shares	(3,005)		(2,862)	5.0
Share premium	15,214		15,214	0.0
Capital reserves	3,475		3,475	0.0
Foreign currency translation reserves	76,700		29,363	161.2
Revaluation reserves for financial assets at FVOCI	(9,501)		1,346	n.a.
Cash-flow hedge reserve	(13,736)		(23)	n.a.
Retained earnings	1,007,854		849,735	18.6
Non-controlling interest	11,058		8,136	35.9
<b>Non-current liabilities</b>	<b>107,334</b>		<b>99,047</b>	<b>8.4</b>
Deferred tax liability	4,663		3,798	22.8
Non-current financial liabilities at FVTPL	70,341		63,819	10.2
Lease liability	12,287		12,722	-3.4
Other non-current liabilities and accruals	14,272		12,830	11.2
Provisions	5,771		5,878	-1.8
<b>Current liabilities</b>	<b>171,002</b>	<b>16)</b>	<b>123,213</b>	<b>38.8</b>
Trade payables	40,485		79,638	-49.2
Contract liabilities	2,344		1,593	47.1
Current tax liabilities	3,211		2,722	18.0
Current financial liabilities at FVTPL	20,929		3,277	538.7
Lease liability	5,202		4,595	13.2
Other current liabilities and accruals	46,342		28,267	63.9
Provisions	1,974		3,121	-36.8
Liabilities directly associated with assets classified as held for sale	50,515		-	n.a.

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

## Consolidated Statement of Changes in Equity

HUFm	Share capital	Share premium	Capital reserve	Treasury shares	Revaluation reserves for financial assets at FVOCI	Foreign currency translation reserve	Retained earnings	Attributable to owners of the parent	Non-controlling interest	Total
Balance at 31 December 2020	18,638	15,214	3,475	(3,791)	974	21,039	751,408	806,957	6,982	813,939
Profit for the period	-	-	-	-	-	-	93,108	93,108	1,013	94,121
Exchange differences arising on translation of subsidiaries	-	-	-	-	-	3,723	-	3,723	8	3,731
Exchange differences arising on translation of associates and joint ventures	-	-	-	-	-	183	-	183	-	183
Changes in the fair value of financial assets at FVOCI	-	-	-	-	1,631	-	-	1,631	-	1,631
Total comprehensive income at 30 September 2021	-	-	-	-	1,631	3,906	93,108	98,645	1,021	99,666
Purchase of treasury shares	-	-	-	(819)	-	-	-	(819)	-	(819)
Transfer of treasury shares	-	-	-	(74)	-	-	70	(4)	-	(4)
Recognition of share-based payments	-	-	-	-	-	-	1,207	1,207	-	1,207
Ordinary share dividend for 2020	-	-	-	-	-	-	(41,934)	(41,934)	-	(41,934)
Dividend paid to non-controlling interest	-	-	-	-	-	-	-	-	(206)	(206)
Sale of subsidiary	-	-	-	-	-	-	-	-	(443)	(443)
<b>Transactions with owners in their capacity as owners for period ended 30 September 2021</b>	-	-	-	(893)	-	-	(40,657)	(41,550)	(649)	(42,199)
<b>Balance at 30 September 2021</b>	<b>18,638</b>	<b>15,214</b>	<b>3,475</b>	<b>(4,684)</b>	<b>2,605</b>	<b>24,945</b>	<b>803,859</b>	<b>864,052</b>	<b>7,354</b>	<b>871,406</b>

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

HUFm	Share capital	Share premium	Capital reserve	Treasury shares	Revaluation reserves for financial assets at FVOCI	Foreign currency translation reserve	Cash-flow hedge reserve	Retained earnings	Attributable to owners of the parent	Non-controlling interest	Total
Balance at 31 December 2021	18,638	15,214	3,475	(2,862)	1,346	29,363	(23)	849,735	914,886	8,136	923,022
Profit for the period	-	-	-	-	-	-	-	196,003	196,003	1,254	197,257
Exchange differences arising on translation of subsidiaries	-	-	-	-	-	48,597	-	-	48,597	1,715	50,312
Exchange differences arising on translation of associates and joint ventures	-	-	-	-	-	(1,260)	-	-	(1,260)	-	(1,260)
Actuarial gain on retirement defined benefit plans	-	-	-	-	-	-	-	400	400	-	400
Changes in the fair value of financial assets at FVOCI	-	-	-	-	(8,472)	-	-	-	(8,472)	-	(8,472)
Reclassification of gain on transfer of equity investments at FVOCI to retained earnings	-	-	-	-	(2,375)	-	-	2,375	-	-	-
Change in fair value of hedging instruments recognised in OCI	-	-	-	-	-	-	(13,713)	-	(13,713)	-	(13,713)
Total comprehensive income at 30 September 2022	-	-	-	-	(10,847)	47,337	(13,713)	198,778	221,555	2,969	224,524
Purchase of treasury shares	-	-	-	(33)	-	-	-	-	(33)	-	(33)
Transfer of treasury shares	-	-	-	(110)	-	-	-	110	-	-	-
Recognition of share-based payments	-	-	-	-	-	-	-	1,165	1,165	-	1,165
Ordinary share dividend for 2021	-	-	-	-	-	-	-	(41,934)	(41,934)	-	(41,934)
Dividend paid to non-controlling interest	-	-	-	-	-	-	-	-	-	(47)	(47)
<b>Transactions with owners in their capacity as owners for period ended 30 September 2022</b>	-	-	-	(143)	-	-	-	(40,659)	(40,802)	(47)	(40,849)
<b>Balance at 30 September 2022</b>	<b>18,638</b>	<b>15,214</b>	<b>3,475</b>	<b>(3,005)</b>	<b>(9,501)</b>	<b>76,700</b>	<b>(13,736)</b>	<b>1,007,854</b>	<b>1,095,639</b>	<b>11,058</b>	<b>1,106,697</b>

Prepared in accordance with IAS 34 Interim Financial Reporting

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

## Consolidated Income Statement – HUF

For the year ended 31 December 2021		For the period ended 30 September			
		2022 Not audited HUFm	Notes	2021 Not audited HUFm	Change %
Audited					
HUFm					
630,595	Revenues	578,787		454,321	27.4
(281,322)	Cost of sales	(242,083)		(202,162)	19.7
349,273	Gross profit	336,704	17)	252,159	33.5
(114,596)	Sales and marketing expenses	(103,447)	18)	(83,793)	23.5
(28,665)	Administration and general expenses	(24,892)	19)	(21,991)	13.2
(61,005)	Research and development expenses	(55,844)	20)	(48,119)	16.1
(9,493)	Other income and other expenses (net)	1,583	21)	(4,514)	n.a.
	Reversal of impairment on financial and contract assets	191		192	-0.5
135,832	Profit from operations	154,295	22)	93,934	64.3
30,106	Finance income	97,039		18,226	432.4
(22,473)	Finance costs	(45,729)		(16,420)	178.5
7,633	Net financial income	51,310	23)	1,806	n.a.
3,110	Share of profit of associates and joint ventures	3,799		2,419	57.0
146,575	Profit before income tax	209,404		98,159	113.3
(856)	Income and deferred tax	(7,312)	24)	(556)	n.a.
(4,539)	Local business tax and innovation contribution	(4,835)		(3,482)	38.9
141,180	Profit for the period	197,257		94,121	109.6
	Profit attributable to:				
139,626	Owners of the parent	196,003	25)	93,108	110.5
1,554	Non-controlling interest	1,254		1,013	23.8
Statement of comprehensive income					
141,180	Profit for the period	197,257		94,121	109.6
	Actuarial gain on retirement defined benefit plans	400		-	n.a.
2,154	Changes in the fair value of equity instruments at FVOCI	(2,367)		2,317	n.a.
2,785	Items that will not be reclassified to profit or loss (net of tax)	(1,967)		2,317	n.a.
	Exchange differences arising on translation of subsidiaries	50,312		3,731	n.a.
	Exchange differences arising on translation of associates and joint ventures	(1,260)		183	n.a.
(23)	Fair value loss on cash-flow hedges	(13,713)		-	n.a.
(1,620)	Changes in fair value of debt instruments at FVOCI	(6,105)		(686)	789.9
6,930	Items that may be subsequently reclassified to profit or loss (net of tax)	29,234		3,228	805.6
9,715	Other comprehensive income for the period	27,267		5,545	391.7
150,895	Total comprehensive income for the period	224,524		99,666	125.3
	Attributable to:				
149,092	Owners of the parent	221,555		98,645	124.6
1,803	Non-controlling interest	2,969		1,021	190.8
<b>HUF Earnings per share (EPS)</b>		<b>HUF</b>		<b>HUF</b>	<b>%</b>
751	Basic	1,052		501	110.0
751	Diluted	1,052		501	110.0

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

## Consolidated Income Statement – EUR

For the year ended 31 December 2021	Not audited EURm	For the period ended 30 September		
		2022 Not audited EURm	2021 Not audited EURm	Change %
1,758.5	Revenues	1,494.1	1,275.3	17.2
(784.5)	Cost of sales	(624.9)	(567.5)	10.1
974.0	Gross profit	869.2	707.8	22.8
(319.6)	Sales and marketing expenses	(267.0)	(235.2)	13.5
(79.9)	Administration and general expenses	(64.3)	(61.7)	4.2
(170.1)	Research and development expenses	(144.2)	(135.0)	6.8
(26.5)	Other income and other expenses (net)	4.1	(12.7)	n.a.
0.9	Reversal of impairment on financial and contract assets	0.5	0.5	0.0
378.8	Profit from operations	398.3	263.7	51.0
84.0	Finance income	250.5	51.2	389.3
(62.7)	Finance costs	(118.0)	(46.1)	156.0
21.3	Net financial income	132.5	5.1	n.a.
8.7	Share of profit of associates and joint ventures	9.8	6.8	44.1
408.8	Profit before income tax	540.6	275.6	96.2
(2.4)	Income and deferred tax	(18.9)	(1.6)	n.a.
(12.7)	Local business tax and innovation contribution	(12.5)	(9.8)	27.6
393.7	Profit for the period	509.2	264.2	92.7
	Profit attributable to:			
389.4	Owners of the parent	506.0	261.4	93.6
4.3	Non-controlling interest	3.2	2.8	14.3
358.59	Average exchange rate (EURHUF)	387.39	356.25	8.7
	Statement of comprehensive income			
393.7	Profit for the period	509.2	264.2	92.7
1.8	Actuarial gain on retirement defined benefit plans	1.0	-	n.a.
6.0	Changes in the fair value of equity instruments at FVOCI	(6.1)	6.5	n.a.
7.8	Items that will not be reclassified to profit or loss (net of tax)	(5.1)	6.5	n.a.
	Exchange differences arising on translation of subsidiaries	129.9	10.5	n.a.
	Exchange differences arising on translation of associates and joint ventures	(3.3)	0.5	n.a.
(0.2)	Fair value loss on cash-flow hedges	(35.4)	-	n.a.
(4.5)	Changes in fair value of debt instruments at FVOCI	(15.7)	(1.9)	726.3
	Items that may be subsequently reclassified to profit or loss (net of tax)	75.5	9.1	729.7
27.1	Other comprehensive income for the period	70.4	15.6	351.3
420.8	Total comprehensive income for the period	579.6	279.8	107.1
	Attributable to:			
415.8	Owners of the parent	571.9	276.9	106.5
5.0	Non-controlling interest	7.7	2.9	165.5
	<b>EUR Earnings per share (EPS)</b>	<b>EUR</b>	<b>EUR</b>	<b>%</b>
2.09	Basic	2.72	1.41	92.9
2.09	Diluted	2.72	1.41	92.9

Prepared in accordance with IAS 34 Interim Financial Reporting.

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

## Consolidated Income Statement – 3 months to September HUF, EUR

	July-September 3 months					
	2022	2021	Change	2022	2021	Change
	Not audited HUFm	Not audited HUFm	%	Not audited EURm	Not audited EURm	%
Revenues	217,807	157,518	38.3	539.8	445.6	21.1
Cost of sales	(87,134)	(71,800)	21.4	(215.3)	(203.1)	6.0
Gross profit	130,673	85,718	52.4	324.5	242.5	33.8
Sales and marketing expenses	(36,009)	(27,047)	33.1	(88.7)	(76.6)	15.8
Administration and general expenses	(8,868)	(7,149)	24.0	(21.9)	(20.2)	8.4
Research and development expenses	(18,769)	(16,528)	13.6	(46.2)	(46.7)	-1.1
Other income and other expenses (net)	(2,459)	(1,975)	24.5	(6.6)	(5.6)	17.9
Reversal of impairment on financial and contract assets	272	115	136.5	0.7	0.3	133.3
Profit from operations	64,840	33,134	95.7	161.8	93.7	72.7
Finance income	28,538	11,279	153.0	69.4	31.8	118.2
Finance costs	(7,271)	(4,719)	54.1	(16.3)	(13.4)	21.6
Net financial income	21,267	6,560	224.2	53.1	18.4	188.6
Share of profit of associates and joint ventures	1,350	968	39.5	3.3	2.8	17.9
Profit before income tax	87,457	40,662	115.1	218.2	114.9	89.9
Income and deferred tax	(2,801)	(1,013)	176.5	(7.0)	(2.9)	141.4
Local business tax and innovation contribution	(2,488)	(1,162)	114.1	(6.3)	(3.3)	90.9
Profit for the period	82,168	38,487	113.5	204.9	108.7	88.5
Profit attributable to:						
Owners of the parent	82,417	38,193	115.8	205.7	107.9	90.6
Non-controlling interest	(249)	294	n.a.	(0.8)	0.8	n.a.
<b>Average exchange rate (EURHUF)</b>				401.02	354.07	13.3
<b>Earnings per share (EPS)</b>	<b>HUF</b>	<b>HUF</b>	<b>%</b>	<b>EUR</b>	<b>EUR</b>	<b>%</b>
Basic	442	205	115.6	1.10	0.58	89.7
Diluted	442	205	115.6	1.10	0.58	89.7

Company name: Gedeon Richter Plc.  
 Company address: 1103 Budapest, Gyömrői út 19-21., Hungary  
 Sector: Pharmaceutical  
 Reporting period: January-September 2022

Telephone: +36-1-431-5764  
 Fax: +36-1-261-2158  
 E-mail address: [investor.relations@richter.hu](mailto:investor.relations@richter.hu)  
 Investor relations manager: Katalin Ördög

## Consolidated Cash-flow Statement

For the year ended 31 December 2021		For the period ended 30 September		
		2022 Not audited HUFm	Notes	2021 Not audited HUFm
	<b>Operating activities</b>			
146,575	Profit before income tax	209,404		98,159
44,922	Depreciation and amortisation	36,232		33,139
(1,425)	Non cash items accounted through Consolidated Income Statement	15,775		2,404
(3,568)	Net interest and dividend income	(3,705)		(1,383)
(8)	Changes in provision for defined benefit plans	(273)		(74)
(939)	Reclass of results on changes of property, plant and equipment and intangible assets	(3,782)		274
(1,391)	Gain on disposal of subsidiaries	-		(1,391)
2,591	Impairment recognised on intangible assets and goodwill	-		-
-	Impairment of securities	743		-
1,590	Expense recognised in respect of equity-settled share-based payments	1,165		1,207
	<i>Movements in working capital</i>			
(36,470)	Increase in trade and other receivables	(85,736)		(24,047)
(20,983)	Increase in inventories	(51,755)		(17,056)
17,173	Increase in payables and other liabilities	25,712		14,282
(27)	Interest paid	(4,660)		(23)
(8,136)	Income tax paid	(9,838)		(6,990)
139,904	<b>Net cash flow from operating activities</b>	<b>129,282</b>		<b>98,501</b>
	<b>Cash flow from investing activities</b>			
(46,127)	Payments for property, plant and equipment	(37,818)	26)	(26,982)
(97,170)	Payments for intangible assets	(5,778)	27)	(93,503)
1,857	Proceeds from disposal of property, plant and equipment	1,425		294
693	Government grant received related to investments	-		692
(143,206)	Payments to acquire financial assets	(21,215)		(99,085)
30,998	Proceeds on sale or redemption on maturity of financial assets	9		5,478
(1,294)	Disbursement of loans net	(15,581)		(2,860)
2,950	Interest received	7,777		937
9	Dividend receives	26		6
-	Net cash outflow on acquisition of subsidiaries	(1,263)		-
2,118	Net cash inflow from disposal of subsidiaries	-		2,118
(249,172)	<b>Net cash flow to investing activities</b>	<b>(72,418)</b>		<b>(212,905)</b>
	<b>Cash flow from financing activities</b>			
(819)	Purchase of treasury shares	(33)		(819)
(42,140)	Dividend paid	(41,981)		(42,140)
(2,055)	Principal elements of lease payments	(905)		(1,663)
(244,846)	Repayment of borrowings	(178,487)		(63,559)
315,119	Proceeds from borrowings	178,487		139,149
25,259	<b>Net cash flow (to)/from financing activities</b>	<b>(42,919)</b>		<b>30,968</b>
(84,009)	<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>13,945</b>		<b>(83,436)</b>
142,068	Cash and cash equivalents at beginning of year	59,856		142,068
1,603	Effect of foreign exchange rate changes on the balances held in foreign currencies	3,354		418
59,662	<b>Cash and cash equivalents at end of period</b>	<b>77,155</b>		<b>59,050</b>

Balance sheet data cannot be reconciled directly due to the reclassification of the assets held for sale.  
 Prepared in accordance with IAS 34 Interim Financial Reporting.

## Notes to Consolidated Financial Statements

Subsequent to the sale of Romanian Wholesale and retail companies of the Group, all related balance sheet item has been reclassified as Assets classified as held for sale or Liabilities directly associated with assets classified as held for sale.

### 13) Non-current assets

Higher levels of Property, plant and equipment in part reflect the impact of the appreciating RUB at the Russian subsidiary of the Group.

The higher levels of Non-current financial assets at fair value through profit or loss (FVTPL) and Non-current financial assets at fair value through other comprehensive income (FVOCI) reflect the purchase of sovereign and corporate bonds, together with investment funds and the impact of changes in fair value and linked FX changes.

### 14) Current assets

Higher Inventories were built up during the first three quarters 2022 at a number of subsidiaries of the Group in order to reduce supply related risks. The extraordinary appreciation of the RUB inflated this figure.

Trade receivables also increased during the reported period. The extraordinary appreciation of the RUB inflated this figure.

### 15) Capital and reserves

Foreign currency translation reserves increased by HUF 47,337m and amounted to HUF 76,700m primarily due to extraordinary exchange rate movements.

Retained earnings amounted to HUF 1,007,854m and increased by HUF 158,119m. The increase was due to profits realized during the reported period.

### 16) Current liabilities

Subsequent to the sale of Romanian Wholesale and retail business of the Group the relevant amount of Trade payables has been reclassified as Liabilities directly associated with assets classified as held for sale.

Levels of Other current liabilities and accruals have increased during the reported period.







## Hedging policy

As the FX composition of Group revenues and expenditures significantly differ, operating profit is exposed to numerous currency fluctuations. The management of foreign exchange risk is based on a strategy approved by the Board of Directors. The financial function regularly evaluates the net groupwide risk exposure and analyses potential hedging opportunities. The Group currently uses only plain vanilla derivative instruments (e.g. forward contracts) for hedging purposes. Hedging transactions are concluded exclusively by the Parent Company and are executed in cases where the risk situation and the potential benefits are considered reasonable. In the fourth quarter of 2021 the Group introduced hedge accounting rules under IFRS9 in respect of the transactions hedging part of the 2022 exposures and we regularly used derivatives to manage FX risk through the year.

In the third quarter of 2022, regarding the USD revenues, the Group maintains a rolling open hedging transaction for six quarters (2022 Q4 - 2024 Q1), thus on 30 September, 2022, there was an open forward stock of USD 255m under USDHUF hedge accounting.

In this quarter we did not make new RUB hedges, so the open „held for trading” foreign currency forwards were RUB 1.0bn and USD 27.4m.

## 24) Income and deferred tax

By virtue of Hungarian Tax Regulations, the base income of the Company, on which corporate tax is applied, may be reduced by the amount of direct costs incurred on R&D activities and 50% of royalties received. Other members of the Group are subject to customary tax regulations effective in their respective countries of incorporation.

In the first nine months to September 2022 the Group reported HUF 7,312m tax expense, which resulted from a HUF 7,214m corporate tax expense, a HUF 3m extraordinary tax expense and a HUF 95m deferred tax expense.

## 25) Net income margin attributable to owners of the parent

33.9 %	20.5%
--------	-------

## 26) and 27) Capital expenditure

Capital expenditure for the Group including payments for intangible assets (HUF 5,778m) totalled HUF 43,596m in the first three quarters 2022 when compared to HUF 120,485m reported for the same period 2021. Figure in the base period includes the settlement of the acquisition of intangible asset Evra contraceptive patch in the amount of HUF 76,721m.

## Corporate matters

### Information regarding Richter shares

The number of shares in issue at 30 September 2022 was unchanged compared to 30 June 2022, i.e. 186,374,860 shares.

The number of shares held by the Parent company in Treasury increased during the third quarter of 2022.

	Ordinary shares				
	30 September 2022	30 June 2022	31 March 2022	31 December 2021	30 September 2021
Number	143,414	136,911	134,828	59,471	268,751
Book value (HUF '000)	1,039,519	988,878	975,485	512,049	2,333,589

On 30 September 2022 the Group's subsidiaries held a total of 3,000 ordinary Richter shares.

In accordance with a repurchase obligation related to employee share bonuses, the Company repurchased 6,503 shares from employees who resigned from the Parent company during the third quarter 2022.

Total number of Company shares held in Treasury including those transferred to ESOT was 553,790 at 30 September 2022.

## Share ownership structure

The shareholder structure at 30 September 2022 is presented in detail in the following table:

Ownership	Ordinary shares	Voting rights	Share capital
	Number	%	%
Domestic ownership	63,501,217	34.10	34.07
State ownership total	126	0.00	0.00
out of which Municipality	126	0.00	0.00
Institutional investors	55,529,034	29.82	29.79
out of which Maecenas	18,637,486	10.01	10.00
Universitatis Corvini Foundation			
out of which Mathias Corvinus	18,637,486	10.01	10.00
Collegium Foundation			
out of which Foundation for			
National Health and	9,777,658	5.25	5.25
Education			
of Medical Doctors			
Retail investors	7,972,057	4.28	4.28
International ownership	122,309,013	65.67	65.62
Institutional investors	122,089,554	65.55	65.50
out of which FMR LLC	9,457,941	5.08	5.07
Retail investors	219,459	0.12	0.12
Treasury shares and shares transferred to ESOT*	553,790	0.22	0.30
Undisclosed ownership	10,840	0.01	0.01
<b>Share capital</b>	<b>186,374,860</b>	<b>100.00</b>	<b>100.00</b>

\* Treasury shares include the combined ownership of the parent company, the ESOT Organisation and the subsidiaries.

Data in the above table were compiled based on the share registry amended with information provided by KELER Zrt. as clearing company, global custodians and nominees. Due to the confidential character of linked investor interests certain investment funds may keep a different record of their respective share capital and/or voting rights.

## Extraordinary announcements


- On 21 October 2022 Richter and Dr.Max BDC, s.r.o. announced that Richter's indirect Romanian subsidiary, Armedica Trading S.R.L has signed a share sale and purchase agreement to divest the Richter Group's Romanian wholesale and retail operations (Pharmafarm S.A. and Gedeon Richter Farmacia S.A., respectively) to Mediplus Exim S.R.L., a Romanian subsidiary of A&D Pharma, both being members of Dr.Max Group. The purchase price is due on the closure of the transaction pending the approval of the Romanian competition authority.
- On 25 October 2022 Richter announced that it has submitted a Type II Variation application for **Ryeqo®** (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) to the European Medicines Agency (EMA) for the treatment of moderate to severe pain associated with endometriosis in adult women of reproductive age with a history of previous medical or surgical treatment for their endometriosis. **Ryeqo®** is already approved since July 2021 by the EMA for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

## Risk management

Richter is committed to long term value creation for its customers, investors, employees and to society at large. In order to succeed in this endeavour Richter operates a risk management system which abides by the highest international standards and best industry practices. Richter views Risk Management as one of the tools for effective Corporate Governance. Management attempts to identify, to understand and to evaluate in due time emerging risks and to initiate such successful corporate responses that ensure both a stable and sustainable operation of the Company and the implementation of its corporate strategy.

Most important risk factors for Richter Group are identified to be the following:

- Risks related to Russian-Ukrainian war
- Direct and indirect impacts of COVID-19 pandemic
- Outstanding contribution of cariprazine to the turnover and profits of the Company
- Higher risks associated with CNS research projects advancing into more advanced phases
- Development and licencing-in of WHC and biosimilar specialty products
- Maintaining the turnover arising from branded generic products and protection of sales levels of our traditional product portfolio
- Ensuring qualified workforce
- Health Authority Regulations
- Customers' high quality expectations
- Intellectual property, patents and litigation
- Environmental sustainability
- Privacy and Information security
- Contracts and liabilities
- Credit and collection
- Capital structure, cash management and financial investments
- Exchange rate volatility and risks related to cost inflation.



## Disclosures

I, the undersigned declare, that Gedeon Richter Plc. takes full responsibility, that the interim management report published today, which contains the Group's 9 months to September 2022 results is prepared in accordance with the applicable accounting standards and according to the best of our knowledge. The report above provides a true and fair view of the financial position of Gedeon Richter Plc. and its subsidiaries included in the consolidation, it presents the major risks and factors of uncertainty, and it also contains an explanation of material events and transactions that have taken place during the reported period and their impact on the financial position of Gedeon Richter Plc. and its subsidiaries included in the consolidation.

Budapest, 8 November 2022



Gábor Orbán  
Chief Executive Officer

The financial statements in this report cover the activities of Gedeon Richter Group ('The Group' or 'Richter Group') and Gedeon Richter Plc. ('The Company' or 'Richter'). EUR and USD amounts have been converted from HUF at average exchange rates for indicative purposes only. Financial statements for twelve months period ended 31 December 2021 are audited. Financial statements for the nine months period ended 30 September 2022 and 30 September 2021 are unaudited.